The first big test of Pfizer’s Arena buyout clears a PhIII in bid to catch up to Zeposia
Pfizer couldn’t let Bristol Myers Squibb be the only Big Pharma with an S1P drug for UC after Zeposia earned an FDA nod last May. Now, Pfizer is inching closer to delivering on its $6.7 billion bid to rival BMS.
Etrasimod, the spotlight of Pfizer’s Arena Pharmaceuticals buyout, cleared a 354-patient Phase III study in UC by meeting the primary endpoint of clinical remission, which looks at stool frequency, rectal bleeding and other symptoms of the inflammatory bowel disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
